What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This research aims to explore the effects of erythropoietin treatment on quality of life in sickle cell disease patients.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 1b/2 trial shows EPO improves quality of life and reduces pain in sickle cell disease, highlighting potential treatment benefits.

This research aims to explore the effects of erythropoietin treatment on quality of life in sickle cell disease patients.
Prospective, open-label study at Lagos University Teaching Hospital and University of Pittsburgh
Patients with sickle cell disease and baseline hemoglobin ≤ 9 g/dL received escalating doses of EPO for 12 weeks
Quality of life assessed using the SF-36 and ASCQ-Me surveys at baseline, 12 weeks, and 24 weeks
Hemoglobin increased from 7.5 to 10.6 g/dL after 12 weeks of EPO (p<0.001)
Significant improvements in SF-36 domains: Physical Functioning (69.3 to 78.1; p=0.045) and Mental Health (69.8 to 78.5; p=0.025)
ASCQ-Me Emotional Impact increased from 53 to 59.3 at 12 weeks (p=0.002)

Oluwole et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark